Russia vaccine bids for Phil emergency use

·1-min read

Russia's Gamaleya Research Institute has applied to the Philippine health regulator for emergency-use authorisation of its COVID-19 vaccine but needs to file further documentation before it can be approved, the regulator says.

Gamaleya's emergency-use application for their Sputnik V vaccine is the third the country's Food and Drug Administration (FDA) has received after Pfizer and AstraZeneca made similar applications.

"The submission was pre-assessed and the applicant was instructed to comply with the lacking documents," FDA Director General Rolando Enrique Domingo said in a statement.

The agency on Friday approved the application of China's Clover Biopharmaceuticals to conduct late-stage clinical trials in the Philippines, he added.

Clover is the second Chinese developer to apply for Phase III clinical trials in the Philippines, following Sinovac Biotech.

In December, the FDA allowed a clinical trial for the vaccine of Johnson & Johnson's unit Janssen.

Philippine President Rodrigo Duterte has vowed to provide free vaccines for the entire 108 million population to help the battered economy recover from the pandemic.

The Philippines has reported more than 482,000 cases and 9,356 deaths, the second-highest totals in Southeast Asia after Indonesia, according to data from Johns Hopkins University.